Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NRG-GY026: Paclitaxel/Carboplatin With or Without HER2-Targeted Subcutaneous Antibodies in HER2-Positive Endometrial Cancer
KCT0009300Phase 3Not yet recruiting
- Sponsor
- Korean Gynecologic Oncology Group
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab, paclitaxel, carboplatin in endometrial cancer (EC), sponsored by Korean Gynecologic Oncology Group. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on KCT0009300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009300.